Aardvark Therapeutics (AARD) Competitors $13.04 -0.88 (-6.32%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. GPCR, PAHC, ABCL, AMPH, NTLA, WVE, ELVN, AUPH, ARDX, and VERVShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Structure Therapeutics (GPCR), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Amphastar Pharmaceuticals (AMPH), Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Structure Therapeutics Phibro Animal Health AbCellera Biologics Amphastar Pharmaceuticals Intellia Therapeutics WAVE Life Sciences Enliven Therapeutics Aurinia Pharmaceuticals Ardelyx Verve Therapeutics Structure Therapeutics (NASDAQ:GPCR) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability. Do analysts recommend GPCR or AARD? Structure Therapeutics currently has a consensus price target of $76.17, suggesting a potential upside of 306.44%. Aardvark Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 153.07%. Given Structure Therapeutics' higher possible upside, equities analysts plainly believe Structure Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of GPCR or AARD? 91.8% of Structure Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer GPCR or AARD? In the previous week, Aardvark Therapeutics had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Aardvark Therapeutics and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.56 beat Aardvark Therapeutics' score of 0.49 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, GPCR or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-21.54Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Is GPCR or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Aardvark Therapeutics N/A N/A N/A SummaryStructure Therapeutics beats Aardvark Therapeutics on 5 of the 9 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$302.01M$2.87B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.04%P/E RatioN/A20.8026.9620.11Price / SalesN/A286.27430.20119.79Price / CashN/A41.1936.8257.86Price / BookN/A7.487.985.56Net Income-$20.59M-$55.04M$3.16B$248.40M7 Day Performance-3.55%2.44%2.39%4.67%1 Month Performance11.64%1.90%2.18%6.64%1 Year PerformanceN/A4.35%33.82%21.31% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$13.04-6.3%$33.00+153.1%N/A$302.01MN/A0.0018GPCRStructure Therapeutics2.6781 of 5 stars$20.62+0.9%$76.17+269.4%-49.7%$1.17BN/A-23.70136PAHCPhibro Animal Health3.6799 of 5 stars$27.99+0.2%$21.80-22.1%+71.9%$1.13B$1.02B35.891,940Trending NewsAnalyst UpgradeABCLAbCellera Biologics2.5514 of 5 stars$3.81+1.5%$8.33+119.0%+41.5%$1.12B$28.83M-6.79500News CoverageAnalyst ForecastAMPHAmphastar Pharmaceuticals4.4152 of 5 stars$23.18-1.7%$32.33+39.5%-39.5%$1.11B$731.97M8.402,028NTLAIntellia Therapeutics4.6944 of 5 stars$10.72-0.1%$33.37+211.4%-51.5%$1.11B$57.88M-2.05600WVEWAVE Life Sciences4.4295 of 5 stars$6.97+3.3%$20.50+194.1%+27.1%$1.05B$108.30M-8.30240ELVNEnliven Therapeutics2.6659 of 5 stars$20.68+0.2%$41.20+99.3%-11.2%$1.01BN/A-10.7750AUPHAurinia Pharmaceuticals2.5668 of 5 stars$7.57+1.0%$11.50+52.0%+34.8%$1.01B$235.13M27.02300ARDXArdelyx4.4333 of 5 stars$4.30+2.5%$10.89+153.5%-17.8%$1.00B$333.61M-19.5290VERVVerve Therapeutics3.4646 of 5 stars$11.23+0.1%$14.57+29.8%+96.3%$999.29M$59.61M-5.32110 Related Companies and Tools Related Companies GPCR Alternatives PAHC Alternatives ABCL Alternatives AMPH Alternatives NTLA Alternatives WVE Alternatives ELVN Alternatives AUPH Alternatives ARDX Alternatives VERV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AARD Stock Alerts